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Abstract
Background: The treatment for the eradication of Helicobacter pylori (H. pylori) is complex; full effectiveness is rarely
achieved and it has many adverse effects. In developing countries, increased resistance to antibiotics and its cost
make eradication more difficult. Probiotics can reduce adverse effects and improve the infection treatment efficacy.
If the first-line therapy fails a second-line treatment using tetracycline, furazolidone and proton-pump inhibitors has
been effective and low cost in Brazil; however it implies in a lot of adverse effects. The aim of this study was to
minimize the adverse effects and increase the eradication rate applying the association of a probiotic compound to
second-line therapy regimen.
Methods: Patients with peptic ulcer or functional dyspepsia infected by H. pylori were randomized to treatment
with the furazolidone, tetracycline and lansoprazole regimen, twice a day for 7 days. In a double-blind study,
patients received placebo or a probiotic compound (Lactobacillus acidophilus, Lactobacillus rhamnosus,
Bifidobacterium bifidum and Streptococcus faecium) in capsules, twice a day for 30 days. A symptom questionnaire
was administered in day zero, after completion of antibiotic therapy, after the probiotic use and eight weeks after
the end of the treatment. Upper digestive endoscopy, histological assessment, rapid urease test and breath test
were performed before and eight weeks after eradication treatment.
Results: One hundred and seven patients were enrolled: 21 men with active probiotic and 19 with placebo plus 34
women with active probiotic and 33 with placebo comprising a total of 55 patients with active probiotic and 52
with placebo. Fifty-one patients had peptic ulcer and 56 were diagnosed as functional dyspepsia. The per-protocol
eradication rate with active probiotic was 89.8% and with placebo, 85.1% (p = 0.49); per intention to treat, 81.8%
and 79.6%, respectively (p = 0.53). The rate of adverse effects at 7 days with the active probiotic was 59.3% and
71.2% with placebo (p = 0.20). At 30 days, it was 44.9% and 60.4%, respectively (p = 0.08).
Conclusions: The use of this probiotic compound compared to placebo in the proposed regimen in Brazilian
patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy or adverse effects.
Trial registration: Current Controlled Trials ISRCTN04714018
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Background
The Helicobacter pylori (H. pylori) eradication is a very
useful tool in preventing the recurrence of peptic ulcer,
in the prevention of gastric cancer and in the treatment
of Malt lymphoma and gastritis [1-4]. However, the regi-
mens used to H. pylori eradication are complex and re-
quire the combination of at least two antibiotics with
acid suppressors that must be administered for several
days [5,6]. Therefore they can lead to many adverse ef-
fects [7], most of them related to the medication but also
alterations in intestinal bacterial flora due to antibiotic
treatment can occur [8,9]. Most patients have trouble to
adhere to treatment and to purchase the drugs that
makes the eradication even more difficult.
Brazil is a densely inhabited developing country with a
rate of H. pylori infection ranging from 58 to 80% of the
adult population [10-17] and most of the infected po-
pulation has low socioeconomic level. Due to specific
characteristics (antibiotic prophylaxis for surgery and
treatment of parasitic infections and or sexually trans-
mitted diseases) the primary resistance to antibiotics
used in the eradication of H. pylori is high (e.g., nitro-
imidazole derivatives) [18-23]. Thus, H. pylori eradica-
tion in Brazil should focus on the use of regimens with
shorter duration and lower cost using highly effective
antibiotics. The treatment of choice is the combination
of proton pump inhibitor with clarithromycin and
amoxicillin which has an efficacy of 85% [24].
The regimen that includes tetracycline, furazolidone
and omeprazole for 7 days has been used as a second-
line treatment, with 75% efficacy [25]; on the other hand
furazolidone results in many adverse effects.
Adverse effects are a common cause of lack of adher-
ence to treatment leading to treatment failure in eradi-
cating H. pylori [6,26]. Treatment failure results in a
higher risk of secondary resistance to antibiotics [27]
and will require the use of new and usually less effective
ones, with longer duration, higher cost and complex reg-
imens [28].
Some adverse effects of treatment are intestinal alter-
ations secondary to changes in the microbiota due to
antibiotic use [29,30]. Probiotics would be an excellent
tool in controlling bacterial overgrowth and reduce these
effects [31-34]. There is also evidence that probiotics
may also inhibit the growth of H. pylori, stimulate an
immunological response and reduce the inflammatory
effects of infection by bacteria [35-37] increasing the
rate of H. pylori eradication [38-40].
This study aimed to detect the rate of eradication effi-
cacy and of side effects in H. pylori treatment with the
combination of a probiotic compound and the regimen
lansoprazole, furazolidone and tetracycline in a pro-
spective, randomized, double-blind, placebo-controlled
study.
Methods
Patients
Developed in 2007 the treatment design had no previous
data in literature for the proposed regimen: association
of 7 days of treatment to H. pylori eradication added to
30 days of probiotic, both initiating at the same time.
The sample calculation was based on a previous study
[25] with a similar regimen, in which 20 mg of omepra-
zole was once a day intake, with tetracycline 500 mg and
furazolidone 200 mg three times a day, for 7 days. By
Fisher's exact test, with unilateral hypothesis, expecting
an increase in the eradication rate of 70 to 90% with
probiotic use, for a power of 0.80 and a significance level
of 0.05, the sample size was 56 patients for each group,
active or placebo. For a 34 to 15% reduction in the rate
of adverse events with probiotic use, for a power of 0.80
and a significance level of 0.05, the sample size was 60
patients for each group.
Patients infected with H. pylori with a previous diag-
nosis of peptic ulcer or functional dyspepsia were invited
to participate in the study.
Inclusion criteria were: more than 18 years old, no pre-
vious treatment for the infection, not having a chronic de-
compensated disease, no use of anti-inflammatory or
antibiotic drugs within 4 weeks prior to enrollment and
sign of informed consent.
Exclusion criteria were: patients who were pregnant or
breastfeeding, patients over 80 years of age or with a his-
tory of gastrointestinal surgery and patients with erosive
esophagitis or users of low-dose aspirin. Patients with
difficulty to understand the treatment or to report dis-
ease symptoms and adverse effects were also excluded.
All patients were followed at the Gastroenterology out-
patient clinic of this Hospital and had been previously di-
agnosed by upper digestive endoscopy. The study was
approved by the ethics and research committee of the
institution: Ethics Committee for Analysis of Research
Projects - CAPPesq – of the Clinical Board of Clinics Hos-
pital, Faculty of Medicine, University of São Paulo.
Diagnoses
All patients were underwent carbon-13 labeled urea
breath test and underwent upper digestive endoscopy. If
a patient was taking proton-pump inhibitors or H2
blockers they discontinued it 10 days before the begin-
ning of the study. The symptomatic use of aluminum
hydroxide was allowed until the beginning of treatment.
During endoscopy mucosal fragments were collected to
perform histological assessment with HE and Giemsa
staining and rapid urease test from the gastric antrum
and gastric body. Eight weeks after treatment comple-
tion patients with peptic ulcer were submitted to the
same examinations and those with functional dyspepsia
underwent urea breath test for heal monitoring.
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Symptom questionnaire
Before treatment, on the seventh and thirtieth day of
treatment and 60 days after its completion, all patients
answered a questionnaire on dyspeptic symptoms and
the most common symptoms related to possible adverse
effects due to treatment (Figure 1). Each symptom was
quantified as absent (zero), mild (1), moderate (2) and
severe (3). The questionnaire allowed the inclusion of
new symptoms (considered as adverse effects) in the as-
sessments after drug administration. We determined the
number and intensity of symptoms in all patient evalua-
tions. Previous symptoms that increased in intensity dur-
ing and after treatment were also considered as adverse
effects.
Treatment
The patients received tablets and capsules in adequate
amount for 7 days of treatment, administered twice a day:
30 mg of lansoprazole, 500 mg of tetracycline and 200 mg
of furazolidone. The probiotic compound consisting of
Lactobacillus acidophilus (1.25 × 109 CFUs), Lactobacillus
rhamnosus (1.25 × 109 CFUs), Bifidobacterium bifidum
(1.25 × 109 CFUs) and Streptococcus faecium (1.25 × 109
CFUs) (Klaire Labs, Reno, NV, USA) was provided in a
bottle with 60 capsules and instructions to be stored in
the refrigerator and to be used regularly during 30 days
(7 days of treatment plus 23 days after cessation of the
antibiotic). The placebo probiotic consisting of capsules of
acidified milk powder (skim milk biologically acidified by
commercial yogurt culture) was also provided at the same
amount and with the same instructions.
All patients were taught at the sight of medication by
the researcher himself and encouraged to maintain full
and regular use of medication considering the benefits of
eradicating H. pylori. They were also asked to maintain
complete abstinence of alcohol, to hamper smoked foods,
chocolate, cheese and eggs and not to use antidepressants
to avoid interaction with Monoamine Oxidase Inhibitor-
like effects of furazolidone during the treatment.
Randomization and study performance
Randomization was carried out using a list obtained by
computer. Patients received their numbers in ascend-
ing order according to study enrollment. This number
corresponded to the randomized regimen for use of
medication with an active or placebo probiotic.
None of the patients knew about the randomization
and investigators, blinded to the randomization, followed
the treatment and performed all examinations independ-
ently. The need to disclose the randomization always
resulted in the exclusion of the patient.
Symptom Absent Mild Moderate Severe
Epigastric pain
Heartburn
Pirosis
Regurgitation
Postprandial  fullness
Nausea
Vomiting
Diarrhea
Abdominal pain
Abnormal taste
Flatulence
Headache
Dizziness
Other (discriminate) 
Values 0 1 2 3
Figure 1 Symptom Questionnaire. Absent: without symptom; Mild: symptom doesn’t interfere with normal activity; Moderate: symptom
interferes with normal activity < 50% of evaluated time; Severe: Symptom interferes with normal activity > 50% of evaluated time, or daily, or
determines the treatment interruption.
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Drug use control was performed 7 and 30 days after
the delivery of medication by counting the remaining
tablets in the blisters and the number of probiotic cap-
sules in the bottle. The use of at least 80% of the tablets
was considered appropriate.
Patients with peptic ulcer were considered cured of in-
fection when they had negative treatment control tests:
rapid urease test, histological analysis and breath test,
performed 60 days after the treatment. For patients with
functional dyspepsia, they were considered cured when
they had a negative urea breath test.
After treatment completion, up to control tests, pa-
tients with severe epigastric pain or heartburn symptoms
were allowed to use aluminum hydroxide pills symptom-
atically. The use of any amount of the antacid agent
characterized the intensity of the symptom as severe.
Enrollment
Assessed for eligibility (n=120)
Not meeting inclusion criteria 
(n=13)
Randomized (n=107)
Allocated to active probiotic       (n= 55)
Received allocated intervention (n= 
55)
Allocated to placebo probiotic   (n= 52)
Received allocated intervention (n= 
52)
Allocation
Lost to follow-up (n=1) refused medication
Discontinued intervention (n=3) noncompliance  
Discontinued intervention (n=3) noncompliance  
Follow-Up
Included in analysis (n=51) Included in analysis (n=49)
Analysis
Figure 2 Probiotic Flow Diagram.
Table 1 Patient allocation in groups of active and placebo
probiotic agent
Active Placebo p
N 55 52
Gender male 21 19
female 34 33 0.86
Disease peptic ulcer* 27 24
dyspepsia 28 28 0.76
Mean age (years) 50.4 48.4 0.78
Pearson Chi-Square.
*29 duodenal 17 gastric 5 gastric + duodenal.
Table 2 Eradication rates in groups of active and
placebo probiotic
Probiotic Active (CI 95%) Placebo (CI 95%) p
Per protocol 89.8% (81-99%) 85.1% (75-96%) p = 0.49
Intention to treat 81.8% (71-92%) 76.9% (65-89%) p = 0.53
Pearson Chi-Square.
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Statistical analysis
The eradication rates were analyzed per intention to treat
and per protocol, with 95% confidence interval (P<0.05).
The Chi-square test method with Pearson’s correction
factor was used to compare variables and a p value < 0.05
was considered statistically significant. The homogeneity
of the groups was evaluated using the nonparametric
Chi-square test.
The distribution of patients in the active probiotic and
placebo groups, age and gender, both for ulcer disease
and for functional dyspepsia, was also evaluated by the
Mann–Whitney test.
The analysis of adverse effect incidence was deter-
mined by Pearson Chi-square test and the intensity of
adverse events at the 7 and 30 day control visits were
evaluated by Mann–Whitney test, using the score
obtained from symptom questionnaire.
The frequencies of the variables, the percentage of
tests and measurements were carried out using Statis-
tical Package for the Social Sciences, 10.0 Version (SPSS
Inc., Chicago, IL, EUA).
Results
Data of included population
The flow diagram of patient enrollment in this study is
shown in Figure 2.
One hundred and seven patients were included in the
study, being 40 were men (37%) and 67 women (63%).
The mean age was 47 years, with a median of 51 years,
ranging from 21 to 74 years. Fifty-five patients (51%)
were allocated in the active probiotic group and 52
(49%) in the placebo probiotic group. Fifty-one patients
(48%) had peptic ulcer: duodenal 29 (57%), gastric 17
(33%) and 5 (10%) gastric and duodenal. Twenty-seven
peptic ulcer patients were in the active probiotic group
and 24 in the placebo group. Fifty-six patients (52%) had
functional dyspepsia, with 28 in the active probiotic
group and 28 in the placebo group (Table 1).
Follow up
One patient in the active probiotic group refused the
medication regimen for eradication.
Six patients did not undergo eradication control: 3 due
to inappropriate use of the eradication regimen (they
were concerned with the adverse effects) and three
abandoned the study after the eradication regimen use.
They were equally divided in the two groups.
Four patients used the eradication regimen and came
for adverse effect control after seven days but then
discontinued probiotic use although they returned for
eradication control. Three were in the placebo probiotic
group and one in the active probiotic group.
Eradication rates
The overall per protocol eradication rate was 87.5% and
per intention to treat, 79.4%. There was no statistical
difference in eradication rate between those who used
active probiotic and placebo, both per protocol (89.8% ×
85.1%) and per intention to treat (81.8% × 76.9%)
Table 2.
There was not statistical difference regarding the efficacy
of eradication per-protocol among patients with peptic
ulcer (91.1%) and those with dyspepsia (84.3%), with
p = 0.31. Moreover per-intention to treat also did not pre-
sent statistical difference (ulcer = 80.4% dyspeptic = 78.6%
p = 0.81).
Although per-protocol efficacy of eradication among
ulcer patients who used active probiotic was higher than
those who used placebo probiotic, the rate was no statis-
tically significant (p = 0.23). Findings were similar for
patients with functional dyspepsia (Table 3).
Adverse effects
At the 7-day visit 69 of 106 (65%) of patients reported side
effects and at the 30-day visit, 50 of 97 patients were still
reporting them (52%). Although there were differences re-
garding the incidence of adverse effects among patients
who used active probiotic and the placebo group they did
not reach statistical significance (Table 4).
The mean intensity of the adverse effects determined
at 7 and 30 days was not different between groups of ac-
tive probiotic and placebo (Table 5).
Table 3 Eradication rates per protocol in peptic ulcer
disease and dyspepsia in groups of active and placebo
probiotic
Peptic ulcer (CI 95%) Dyspepsia (CI 95%)
Active probiotic 95.8% (87-100%) 84.0% (74-100%)
Placebo probiotic 85.7% (69-100%) 84.6% (70-99%)
Pearson Chi-Square p = 0.23 p = 0.95
Table 4 Incidence of adverse effects in groups of active
and placebo probiotic at 7 and 30-day visits
Visit Active probiotic Placebo probiotic p
7 day 32/54 (59.3%) 37/52 (71.2%) 0.20
30 day 21/49 (44.9%) 29/48 (60.4%) 0.08
Pearson Chi-Square.
Table 5 Intensity of adverse effects in groups of active
and placebo probiotic at 7 and 30 day visits
Visits Active probiotic Placebo probiotic p
7 day mean/sum rank 49/2,642 58/3,028 0.11
30 day mean/sum rank 48/2,329 51/2,423 0.58
Mann–Whitney Test.
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Discussion
The triple treatment regimen used in this study favored the
short-term therapy (7 days), convenient dosage (twice a
day) and simplicity (3 units) aimed at low cost, easy under-
standing and greater adherence with antibiotics which in
our country show low bacterial resistance. These character-
istics make treatment adherence depend more on the ad-
verse effects that treatment complexity when compared to
the classic regimen including omeprazole, clarithromycin
and amoxicillin [24].
The regimen used in this study differed from a previ-
ously tested treatment [25] with furazolidone and tetra-
cycline administered 3 × day and the proton-pump
inhibitor once a day; in this regimen the drugs were
equally administered twice a day for 7 days. In the first
regimen the eradication effectiveness per-protocol was
75%. In this study, the per-protocol eradication efficacy
was higher: 87.5% (perhaps by greater simplicity of the
regimen) and this rate was similar to that obtained in
our country, with a regimen that included proton-pump
inhibitor, clarithromycin and amoxicillin: 88.8% (per
protocol), also a short-duration regimen, preferably
used as first-line eradication of H. pylori [24]. The dif-
ferences between the regimens, PPI + amoxicillin +
clarithromycin twice a day for 7 days or PPI once a
day + Tetracycline + Furazolidone 3 times a day for 7
days were the incidence of severe adverse effects that
was much lower for clarithromycin with amoxicillin
(3.7%) than with furazolidone with tetracycline (15%).
This study associated a probiotic compound to the
antibiotic regimen targeting a lower rate of the adverse
effects. The incidence of adverse effects were higher
than expected probably because of the use of a standard
symptom questionnaire. Unfortunately although there
was a difference in incidence and severity of adverse ef-
fects between the active probiotic and placebo groups,
no statistical significance was observed.
In the literature studies have observed increase of eradi-
cation rate and decrease of adverse effects in H. pylori
eradication when a probiotic is associated with the treat-
ment of the infection [39-43]. Ojetti and coworkers [44]
used a single strain of lactobacillus with 1×108 CFUs for
14 days also associated with a triple regimen of eradication
(PPI + Levofloxacin + Amoxicillin) with 7 days in duration
and obtained both increasing eradication and a reduction
in adverse effects. Du and colleagues [45] also with a 7
days triple eradication regimen (PPI + Amoxicillin +
Clarithomycin) also with 14 days treatment with a single
strain of bacillus (3×107 CFUs) in patient groups approxi-
mately equal to ours also obtained eradication increased
and adverse effects decreased.
Others studies achieved a decrease of adverse effects
without an increase of eradication rate [34,44,46,47].
Among them, one of Manfredi at al. [46] associated a
compound of the four different probiotics and prebiotics
for 10 days in a sequential treatment for eradication of
H. pylori and observed a reduction of adverse effects, al-
though no increase in eradication.
On the other hand some studies didn’t verified signifi-
cant benefits in probiotic use [48-50]. Yoon [49] and co-
workers joined a compound of 4 probiotics, for 4 weeks,
to a treatment of 14 days second-line regimen for H. pylori
eradication, with PPI + amoxicillin + moxifloxacin that
did not increase eradication or reduce the adverse effects.
The different results are probably due to the different
products used, their different concentrations, probiotic
strain, dose and duration of use and also the strain of
H. pylori in question, as suggested by Vitor [38] and Wil-
helm [33].
Considering the fact that the use of a probiotic agent
also adds more complexity to the process as it increases
treatment duration, the benefit of attaining a lower inci-
dence of adverse effects or higher eradication effec-
tiveness with longer treatment duration is debatable,
especially because the difference did not reach statistical
significance, as also stated by Medeiros et al. [51].
However if probiotics can reduce the adverse effects of
H. pylori eradication it could enable greater adherence
to treatment and could increase the eradication rate by
intention to treat.
Thus it is necessary to seek other probiotic combina-
tions or other presentations or other dosages or other
treatment duration to achieve these goals.
Conclusions
The probiotic compound used in the present study
(Lactobacillus acidophilus, Lactobacillus rhamnosus,
Bifidobacterium bifidum and Streptococcus Faecium),
administered for 30 days associated to the H. pylori
eradication regimen: Lansoprazole 30 mg, Tetracycline
500 mg and Furazolidone 200 mg administered twice a
day for 7 days did not show an increase in bacterial
eradication effectiveness or decrease in adverse effects
of H. pylori eradication treatment in Brazilian patients
with peptic ulcer and functional dyspepsia.
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